Business Context and Reporting Period
Company: Delcath Systems, Inc. (DCTH)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Delcath is an interventional oncology company focused on treating cancers primary or metastatic to the liver. Its lead product, the HEPZATO KIT (FDA-approved for uveal melanoma), is sold in the U.S., while the CHEMOSAT device is sold in Europe. The company is currently advancing Phase 2 clinical trials for HEPZATO in metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC).
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2026 |
6 Months Ended June 30, 2026 |
6 Months Ended June 30, 2025 |
|---|---|---|---|
| Total Revenue | $29,133 | $54,127 | $43,940 |
| Gross Profit | $26,148 | $47,406 | $37,777 |
| Gross Margin | 89.8% | 87.6% | 86.0% |
| Operating Income | $2,395 | $758 | $3,232 |
| Net Income | $2,668 | $1,598 | $3,766 |
| Diluted EPS | $0.07 | $0.04 | $0.09 |
| Cash & Cash Equivalents | $47,521 (as of June 30, 2026) | ||
| Short-term Investments | $48,381 (as of June 30, 2026) | ||
| Total Liabilities | $15,873 (as of June 30, 2026) | ||
| Operating Cash Flow (6mo) | $6,569 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 20.6% year-over-year for the six months ended June 30, 2026 ($54.1M vs. $43.9M), driven primarily by commercial expansion of HEPZATO in the U.S. (U.S. revenue: $50.4M vs. $40.5M).
- Profitability Decline: While the company remained profitable, Net Income for the six months ended June 30, 2026, decreased to $1.6M from $3.8M in the prior year period. Operating income dropped to $0.8M from $3.2M.
- Expense Increases:
- R&D Expenses: Increased 70% year-over-year ($20.2M vs. $11.9M) due to expanded clinical teams and ongoing Phase 2 trials for mCRC and mBC.
- SG&A Expenses: Increased 17% year-over-year ($26.4M vs. $22.7M) due to commercial expansion and marketing activities.
- Share Repurchases: The company repurchased approximately 945,665 shares under its $25M program, spending approximately $9.0M total (including prior year activity), with $16.0M remaining available.
Guidance, Outlook, and Risks
- Clinical Outlook:
- CHOPIN Trial Results: Announced October 2025, showing significant improvement in progression-free survival and overall survival when CHEMOSAT was combined with immune checkpoint inhibitors versus monotherapy.
- Phase 2 Trials: Enrollment began in Q3 2025 for mCRC (expected readout end of 2027) and Q3 2026 for mBC (expected readout end of 2028).
- Liquidity: Management believes current cash, equivalents, and investments ($95.9M total) are sufficient to fund operations for at least 12 months.
- Regulatory & Reimbursement: The company is subject to the National Drug Rebate Agreement (NDRA) and Pharmaceutical Pricing Agreement (PPA) with CMS, requiring rebates for Medicaid usage and sales at 340B prices. No accrued rebates were recorded as of June 30, 2026.
- Risks:
- Customer Concentration: Two customers accounted for 29.2% of revenue in the first six months of 2026. The largest customer represented 19.0% of accounts receivable.
- Supply Chain: Risks related to geopolitical events and raw material shortages, though the company maintains stockpiled inventory.
- Legal: A contingent liability of $0.6M remains related to a settled dispute with medac GmbH.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $95.9M liquidity position against the accelerating R&D burn rate ($20.2M in 6 months) for upcoming Phase 2 trials.
- Customer Concentration: Assess the risk associated with the top two customers representing nearly 30% of revenue and the potential impact of payment delays.
- Reimbursement Impact: Monitor the financial impact of the NDRA and 340B pricing agreements on future gross margins as Medicaid and 340B sales volumes grow.
- Clinical Milestones: Track enrollment progress and safety data for the mCRC and mBC Phase 2 trials, which are critical for future revenue expansion beyond uveal melanoma.
- Share Repurchase Activity: Review the remaining $16.0M authorization and the company's strategy for capital allocation between buybacks and clinical development.